Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [18F]AZD4694
AZD4694 · 2 trials · 2 indications
Measuring the maximum chemical mass not causing any significant alteration of the amyloid status (unit = micrograms)
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | \[18F\]4694 |
| Part 1 Cohort 1 | EXPERIMENTAL | Patients with mild to moderate Alzheimer's Disease |
| Part 1 Cohort 2 | EXPERIMENTAL | Patients with mild to moderate Alzheimer's Disease. To run if Maximum Detective Mass is detected in cohort 1. |
| Part 2 | EXPERIMENTAL | Healthy Volunteers |
| Name | Type | Description |
|---|---|---|
| [18F]AZD4694 | DRUG | \[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants. |
| [18Fluor]AZD4694 | OTHER | Low mass dose below 5ug. High mass dose around 40 and 50 ug. |
Inclusion Criteria: * Male or female, of any race or/ethnicity * ECG, vital signs, and clinical laboratory values are within normal limits at enrollment or deemed not clinically significant by the physician Exclusion Criteria: * Significant recent (within 6 months) history of neurological (includ...
Top 20 of 30 competitors
AZD4694 is an investigational small molecule PET imaging agent being developed by AstraZeneca for neurology applications. It is studied as a radioligand for positron emission tomography measurements of fibrillar amyloid burden, and it has also been evaluated for maximum diagnostic mass of [18Fluor]AZD4694. It is not an approved therapy.
AZD4694 is used in Alzheimer's disease research as a PET imaging radioligand to measure fibrillar amyloid burden in the brain. One Phase 2 study compared PET measurements of fibrillar amyloid burden, and a separate Phase 1 study assessed varying mass of AZD4694 on radioligand binding parameters in healthy volunteers and patients with Alzheimer's disease.
AZD4694 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical studies evaluating the compound as a PET radioligand for amyloid imaging in Alzheimer's disease and related diagnostic mass assessments.
AZD4694 has been studied in Phase 1 and Phase 2 clinical trials. The Phase 2 study, NCT00991419, compared PET measurements of fibrillar amyloid burden and is completed. The Phase 1 study, NCT01325402, examined varying mass of AZD4694 on radioligand binding parameters and is also completed. It is investigational and not approved.
AZD4694 has been evaluated in two completed trials. NCT00991419 was a Phase 2 study comparing PET measurements of fibrillar amyloid burden, enrolling 25 participants in the United States. NCT01325402 was a Phase 1 open-label PET study assessing varying mass of AZD4694 on radioligand binding parameters, enrolling 16 participants in Sweden.
Yes, [18F]AZD4694 is another name for AZD4694. The bracketed notation reflects the fluorine-18 radiolabel used in the compound for positron emission tomography imaging. Searches for either name refer to the same AstraZeneca PET radioligand being studied for fibrillar amyloid burden measurement.